Juno, a platform designed to help manage corporate guest travel, raised $2 million in seed funding, the company announced Tuesday. The round was led by Seattle-based Madrona and Bungalow Ventures.… Read More
Two industrial designers who helped create and launch the first Amazon Go cashierless convenience store have a new baby, as some founders like to refer to their startups. Newly launched… Read More
New funding: Eliem Therapeutics, a new Seattle biotech startup led by former Juno Therapeutics exec Bob Azelby, raised $80 million to develop clinically-validated therapies for pain and depression. The pipeline:… Read More
— Microsoft added to its senior leadership team with the appointment of Christopher Young as executive vice president of business development. Young previously served as CEO of cybersecurity giant McAfee… Read More
— The former head of Juno Therapeutics, Hans Bishop, signed on as CEO of Grail, a Bay Area biotech focused on the early detection of cancer. Bishop replaces former Grail… Read More
When you walk into Juno Therapeutics‘ new headquarters in Seattle, your eyes are immediately drawn to the view. The office’s 12th-floor reception desk offers a stunning panorama of the Olympic mountains,… Read More
Seattle-based biotech juggernaut Juno Therapeutics delivered mixed results in its 2017 quarter one earnings report Thursday — the first financial report from the company since it announced it was pulling the… Read More
ReplyYes, a fast-growing, chat-based commerce startup, announced three additions to the company’s executive board this week: former Zulily engineer Trevor Inman, former Qumulo exec Brett Goodwin, and Blackberry and Warner Music… Read More
Juno Therapeutics, which spun out of Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute just three years ago, today issued financial results for the… Read More
Robert Nelsen may not be a household name in venture capital circles — certainly not the way that Reid Hoffman, John Doerr and Fred Wilson are known. But the Seattle… Read More
Seattle is well known for making airplanes, coffee and software. But when it comes to cutting-edge biotechnology and health services, the region doesn’t always get top billing. That point of… Read More
Juno Therapeutics is no stranger to huge financing deals. The Seattle biotech company, which emerged on the scene just two years ago, raised $314 million in venture capital financing before… Read More
The groundbreaking for the new headquarters and R&D center of Juno Therapeutics at the Alexandria Center brings increased promise to the booming and fast-growing Seattle biotech industry. “We hope [this new building] will… Read More
Shares of Juno Therapeutics jumped more than six percent on Tuesday after the Seattle biotechnology company announced its acquisition of Waltham, Massachusetts-based X-BODY Inc. X-BODY is small, employing just nine… Read More
Fast-growing Juno Therapeutics — fresh off its IPO from last December — is expanding its presence in its hometown of Seattle. The company just entered into a lease agreement for… Read More
Juno Therapeutics, the fast-growing Seattle biotechnology company, today announced that it plans to open a new manufacturing facility in Bothell for its cell therapy products. The facility will open in… Read More
It was a busy year for publicly-traded tech companies in the Seattle region, with plenty of winners and losers. The region’s two heavyweight tech titans produced opposite results on Wall… Read More
Juno Therapeutics is just a little more than a year old, but the Seattle area biotech startup has quite the following on Wall Street. The company’s stock closed today at… Read More
Juno Therapeutics, a heavily-funded cancer research company that was formed just 16 months ago, priced its initial public offering Thursday night at $24 per share. That was above the expected… Read More
Juno Therapeutics boosted its IPO range at $21 to $23 per share today as the fast-growing Seattle biotech startup prepares to become a publicly-traded company. Juno, which filed to go public… Read More
—Liz Howekamp Powell, the former vice president of marketing at WhitePages, has landed a new gig as head of organic growth at Seattle startup Pro.com. The home improvement marketplace is… Read More
Seattle’s biotech industry has been on an up-and-down roller coaster ride over the past 12 months, with layoffs and R&D center closures as well as huge financing rounds. Now, the… Read More
Juno Therapeutics stunned the startup community earlier this week when it announced $134 million in venture funding, bringing total financing in the Seattle cancer research startup to $310 million. Amazingly,… Read More
Juno Therapeutics wants to wipe out cancer by rewiring the body’s immune system, and it’s receiving some serious investor backing in order to do so. The Seattle-based startup today announced… Read More
Seattle biotechnology startup Juno Therapeutics, which is developing immunotherapies for cancer, said it has closed its series A financing round at $176 million. That marks one of the largest early-stage… Read More
Researchers from Seattle who are finding ways to eliminate cancer are bringing in some serious funding today. On the same day the Fred Hutchinson Cancer Research Center announced a $20 million donation… Read More
—INRIX, the Kirkland company that uses data to reduce traffic congestion, has named Mike Gerling to the board. He previously served as the North America chief operating officer of mapping provider Tele… Read More
Propelled by a massive financing round in upstart Seattle biotechnology company Juno Therapeutics, venture capital investments in the Pacific Northwest soared during the fourth quarter as just over half a… Read More
If you want to know about Earth’s next visitor to Jupiter, a familiar face with a familiar bow tie is here to help. That’s right, Bill Nye is back talking… Read More
